Trial involving high risk and elderly people shows Moderna’s Covid-19: vaccine is nearly 95% effective

UK government has secured 5 million doses of the covid-19 vaccine candidate (mRNA-1273) from US biotech company Moderna after interim analysis of its phase III trial showed it was 94.5% effective and could be delivered to UK spring 2021.

SPS commentary:

This news comes just over a week after Pfizer announced that its covid-19 vaccine candidate was more than 90% effective, following its interim analysis. Neither Pfizer nor Moderna have published their full results yet, only releasing information through press releases.

The European Medicine Agency is also set to start rolling review of mRNA-1273 COVID-19 vaccine. The decision to start rolling review is based on this first interim analysis. Moderna expects marketing authorisation to be based on a final analysis of 151 cases and median follow-up of > 2 months.

Source:

British Medical Journal

Resource links:

Pfizer press release

European Medicine Agency (EMA) starts rolling review of mRNA-1273 COVID-19 vaccine by Moderna Biotech Spain